Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile

Introduction: Red Salud UC is an Academic health network where HIV-infected patients from the public and private health system are followed by a multidisplinary team. Aim: To determine virologic and immunologic response after 144 weeks of starting first antiretroviral therapy in these patients. Meth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ceballos,M. Elena, Rojas,Álvaro, Donato,Paulina, Huilcamán,Marcos, Rivera,Gonzalo, López,Tania, Gutiérrez,Catalina, Labarca,Jaime, Pérez,Carlos
Lenguaje:	English
Publicado:	Sociedad Chilena de Infectología 2016
Materias:	HIV Antiretroviral therapy Outcome Academic Health Network
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000500007
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0716-10182016000500007
record_format	dspace
spelling	oai:scielo:S0716-101820160005000072017-01-11Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in ChileCeballos,M. ElenaRojas,ÁlvaroDonato,PaulinaHuilcamán,MarcosRivera,GonzaloLópez,TaniaGutiérrez,CatalinaLabarca,JaimePérez,Carlos HIV Antiretroviral therapy Outcome Academic Health Network Introduction: Red Salud UC is an Academic health network where HIV-infected patients from the public and private health system are followed by a multidisplinary team. Aim: To determine virologic and immunologic response after 144 weeks of starting first antiretroviral therapy in these patients. Methods: A retrospective analysis of adult HIV patients attended between 1992 and 2011 was performed. Demographic and clinical characteristics, antiretroviral therapies data and immunologic and virologic outcomes were collected. CD4 count and HIV viral load changes up to 144 weeks after initiation of antiretroviral therapy were analyzed. Results: 860 patients were included in the analyses. Median age was 42 years, 93% were men. Median CD4+ count at baseline was 202 cells/mm³. The most used ART regimen was zidovudine/lamivudine plus efavirenz. First line anti-retroviral therapy was changed in 42% patients, being the most common cause, drug toxicity. At week 144, median CD4+ lymphocyte cell count was 449 cells/mm³. Ninety percent and 96% had undetectable viral load measured as < 50 copies/mL or < 400 copies/mL respectively. Discussion: First report of a university cohort, with CD4 and viral load follow up for 144 weeks, including Chilean patients from public and private system. After initiation of ART, an excellent immunologic and virologic response was observed in this cohort.info:eu-repo/semantics/openAccessSociedad Chilena de InfectologíaRevista chilena de infectología v.33 n.5 20162016-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000500007en10.4067/S0716-10182016000500007
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	HIV Antiretroviral therapy Outcome Academic Health Network
spellingShingle	HIV Antiretroviral therapy Outcome Academic Health Network Ceballos,M. Elena Rojas,Álvaro Donato,Paulina Huilcamán,Marcos Rivera,Gonzalo López,Tania Gutiérrez,Catalina Labarca,Jaime Pérez,Carlos Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
description	Introduction: Red Salud UC is an Academic health network where HIV-infected patients from the public and private health system are followed by a multidisplinary team. Aim: To determine virologic and immunologic response after 144 weeks of starting first antiretroviral therapy in these patients. Methods: A retrospective analysis of adult HIV patients attended between 1992 and 2011 was performed. Demographic and clinical characteristics, antiretroviral therapies data and immunologic and virologic outcomes were collected. CD4 count and HIV viral load changes up to 144 weeks after initiation of antiretroviral therapy were analyzed. Results: 860 patients were included in the analyses. Median age was 42 years, 93% were men. Median CD4+ count at baseline was 202 cells/mm³. The most used ART regimen was zidovudine/lamivudine plus efavirenz. First line anti-retroviral therapy was changed in 42% patients, being the most common cause, drug toxicity. At week 144, median CD4+ lymphocyte cell count was 449 cells/mm³. Ninety percent and 96% had undetectable viral load measured as < 50 copies/mL or < 400 copies/mL respectively. Discussion: First report of a university cohort, with CD4 and viral load follow up for 144 weeks, including Chilean patients from public and private system. After initiation of ART, an excellent immunologic and virologic response was observed in this cohort.
author	Ceballos,M. Elena Rojas,Álvaro Donato,Paulina Huilcamán,Marcos Rivera,Gonzalo López,Tania Gutiérrez,Catalina Labarca,Jaime Pérez,Carlos
author_facet	Ceballos,M. Elena Rojas,Álvaro Donato,Paulina Huilcamán,Marcos Rivera,Gonzalo López,Tania Gutiérrez,Catalina Labarca,Jaime Pérez,Carlos
author_sort	Ceballos,M. Elena
title	Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
title_short	Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
title_full	Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
title_fullStr	Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
title_full_unstemmed	Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile
title_sort	virological and immunological outcomes to antiretroviral therapy in hiv-infected patients of an academic medical center in chile
publisher	Sociedad Chilena de Infectología
publishDate	2016
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000500007
work_keys_str_mv	AT ceballosmelena virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT rojasalvaro virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT donatopaulina virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT huilcamanmarcos virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT riveragonzalo virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT lopeztania virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT gutierrezcatalina virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT labarcajaime virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile AT perezcarlos virologicalandimmunologicaloutcomestoantiretroviraltherapyinhivinfectedpatientsofanacademicmedicalcenterinchile
_version_	1718440409124831232

Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile

Ejemplares similares